Literature DB >> 21208245

A 13-nation population survey of upper gastrointestinal symptoms: prevalence of symptoms and socioeconomic factors.

S Haag1, J M Andrews, J Gapasin, G Gerken, A Keller, G J Holtmann.   

Abstract

BACKGROUND: Previous data collected in separate studies using various different survey instruments have suggested some variability in the prevalence of symptoms between nations. However, there is a lack of studies which assess and compare the prevalence of upper gastrointestinal symptoms contemporaneously in various countries using a uniform, standardised method. AIM: To determine the prevalence of upper gastrointestinal (UGI) symptoms in 13 European countries, and the association between socioeconomic factors and symptoms using a standardised method.
METHODS: A representative age- and gender-stratified sample of 23,163 subjects (aged 18-69 years) was surveyed.
RESULTS: The prevalence of UGI symptoms was 38%. UGI symptoms were most prevalent in Hungary [45%, 95% confidence interval (CI): 42.2-48.4] and lowest in the Netherlands (24%, 95% CI: 21.0-26.2). UGI symptoms were more prevalent in women (39%, 95% CI: 38.4-39.6) vs. men (37%, 95% CI: 36.4-37.6). Heartburn (24%, 95% CI: 23.4-24.6) and acidic reflux (14%, 95% CI: 13.6-14.4) were most common. With age, the prevalence of UGI symptoms decreased (e.g. 18-29 years: 43%, 95% CI: 41.4-44.3 vs. 50-69 years: 33%, 95% CI: 32.3-34.4); in contrast, the frequency of symptom episodes/year increased with age (e.g. 18-29 years: 11.3 episodes per years, 95% CI: 10.5-12.1 vs. 50-69 years: 21.8, 95% CI: 20.7-22.9). Socioeconomic status as measured by gross domestic product was inversely associated with symptoms and in total, socioeconomic factors, gender, body mass index, smoking habits and alcohol consumption explained 83% of the variance of UGI symptoms.
CONCLUSIONS: There are marked differences in the country specific prevalence of upper gastrointestinal complaints. Socioeconomic factors are closely associated with the prevalence of upper gastrointestinal symptoms.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21208245     DOI: 10.1111/j.1365-2036.2010.04564.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  [Functional gastrointestinal diseases].

Authors:  J Keller; P Layer
Journal:  Internist (Berl)       Date:  2013-11       Impact factor: 0.743

Review 2.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

3.  Prevalence and characteristics of dyspepsia among college students in Zhejiang Province.

Authors:  Meng Li; Bin Lu; Li Chu; Hong Zhou; Ming-Yan Chen
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

4.  Dyspepsia in Iran: SEPAHAN Systematic Review No. 3.

Authors:  Ehssan Amini; Ammar Hassanzadeh Keshteli; Marsa Sadat Hashemi Jazi; Pegah Jahangiri; Peyman Adibi
Journal:  Int J Prev Med       Date:  2012-03

5.  Categorization of upper gastrointestinal symptoms is useful in predicting background factors and studying effects and usages of digestive drugs.

Authors:  Nobutake Yamamichi; Takeshi Shimamoto; Yoshiki Sakaguchi; Yu Takahashi; Shinya Kodashima; Chiemi Nakayama; Chihiro Minatsuki; Satoshi Ono; Satoshi Mochizuki; Rie Matsuda; Itsuko Asada-Hirayama; Keiko Niimi; Mitsuhiro Fujishiro; Yosuke Tsuji; Chihiro Takeuchi; Hikaru Kakimoto; Osamu Goto; Toru Mitsushima; Kazuhiko Koike
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

6.  A real-world evidence study evaluating Geffer effervescent granules for the symptomatic relief of digestive symptoms.

Authors:  Matteo Alemanni; Raffaella de Salvo; Barbara Moroni; Andreas Ehret
Journal:  SAGE Open Med       Date:  2022-03-29

7.  Gastrointestinal symptoms are still prevalent and negatively impact health-related quality of life: a large cross-sectional population based study in The Netherlands.

Authors:  Merel M Tielemans; Jeroen Jaspers Focks; Leo G M van Rossum; Ties Eikendal; Jan B M J Jansen; Robert J F Laheij; Martijn G H van Oijen
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

8.  Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus.

Authors:  Sejeong Park; So Young Park; Yu Jin Kim; Soo Min Hong; Suk Chon; Seungjoon Oh; Jeong Taek Woo; Sung Woon Kim; Young Seol Kim; Sang Youl Rhee
Journal:  Diabetes Metab J       Date:  2016-04-21       Impact factor: 5.376

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.